Related Experiment Video
Updated: Jul 3, 2026
09:54
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Wegener's granulomatosis effectively treated with rituximab: a case study
Bozena Kowalewska1, Jacek Szechiński, Eliza Roszkowska
1Department of Rheumatology and Internal Diseases of the University Clinical Hospital, Wrocław, Poland. bkhematol@wp.pl
Polskie Archiwum Medycyny Wewnetrznej
|July 16, 2008
Summary
Wegener's granulomatosis (WG), a severe autoimmune disease, can be refractory to standard treatments. Rituximab offers a successful therapeutic option for managing refractory WG and preventing severe lung damage.
Area of Science:
- Rheumatology
- Immunology
- Pulmonology
Background:
- Wegener's granulomatosis (WG) is a systemic necrotizing vasculitis affecting the respiratory tract and kidneys, often associated with cytoplasmic antineutrophil cytoplasmic antibodies (cANCA).
- Standard treatment involves cyclophosphamide and corticosteroids, with rituximab considered for refractory cases.
Observation:
- A 38-year-old woman with severe WG showed disease progression despite standard therapy and additional infliximab and methotrexate.
- Pulmonary involvement led to progressive lung destruction and respiratory insufficiency.
Findings:
- Intravenous rituximab (500 mg weekly for four infusions) induced partial remission and halted lung deterioration.
- Subsequent bi-weekly rituximab infusions achieved remission, allowing the patient's return to normal activities.
Implications:
- Rituximab is a viable and effective treatment for severe, refractory Wegener's granulomatosis.
- Early consideration of rituximab may prevent severe pulmonary complications and improve patient outcomes.